CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) vs. capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI study group
DOI 10.1055/s-2007-988128
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Reinacher-Schick, M Geißler, U Graeven, W Freier, S Hegewisch-Becker, D Arnold, S Kanzler, G Dietrich, HJ Schmoll, W Schmiegel
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2007
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Bevacizumab (Bev) combined with 5-FU/FA and both, irinotecan or oxaliplatin are standard regimens for mCRC. Recently, a phase III trial has demonstrated that infusional 5-FU can be substituted by capecitabine (cape) when combined with oxaliplatin and Bev whereas conflicting data are available for feasibility and efficacy of cape/irinotecan combinations. Aim: This randomized phase II trial was to compar…
Zitieren
Zitierempfehlung
A Reinacher-Schick, M Geißler, U Graeven, W Freier, S Hegewisch-Becker, D Arnold, S Kanzler, G Dietrich, HJ Schmoll, W Schmiegel (2007) Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) vs. capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI study group. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-2007-988128
Mit CareLit weiterarbeiten